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Abstract 24 
Obesity has been implicated as a risk factor for insulin resistance and cardiovascular diseases 25 
(CVDs). Although the association between obesity and CVD is a well-established phenomenon, the 26 
precise mechanisms remain incompletely understood. This has led to a relative paucity of therapeutic 27 
measures for the prevention and treatment of CVD and associated metabolic disorders. Recent 28 
studies have shed light on the pivotal role of prolonged endoplasmic reticulum stress (ERS)-initiated 29 
activation of the unfolded protein response (UPR), and the ensuing chronic low-grade inflammation, 30 
and altered insulin signaling in promoting obesity-compromised cardiovascular system (CVS). In this 31 
aspect, potential ways of attenuating ERS-initiated UPR signaling seems a promising avenue for 32 
therapeutic interventions. We review intersecting role of obesity-induced ERS, chronic inflammation, 33 
insulin resistance, and oxidative stress in the discovery of targeted therapy. Moreover, this review 34 
highlights the current progress and strategies on therapeutics being explored in preclinical and 35 
clinical research to modulate ERS and UPR signaling. 36 
1 Introduction 37 
Obesity is a major health problem worldwide and often associated with an increased prevalence of 38 
cardiovascular diseases (CVDs) and premature death. According to the World health organization 39 
(WHO), there were over 1.9 billion overweight adults in 2016, of whom 650 million were obese (WHO, 40 
2018). There are also 2.6 million estimated annual deaths associated with obesity-related diseases.  41 
An increase in the prevalence of obesity entails an increase in confounding cardiometabolic disorders. 42 
Some of these obesity-linked cardiometabolic health problems include CVD, Type-2 diabetes mellitus 43 
(T2DM), hypertension, myocardial infarction, atherosclerosis, and stroke (Poirier, Giles, et al., 2006). 44 
According to WHO, an estimated 17.7 million people died from CVD in 2015, of which 13% were 45 
because of coronary heart disease (WHO, 2017). Epigenetics and traditional risk factors such as 46 
hypercholesterolemia, hyperlipidemia, T2DM, and hypertension, are significant contributors to the 47 
increasing prevalence of CVD. However, obesity is considered an independent factor for the increased 48 
prevalence of different subtypes of CVD including hypertension, stroke, coronary heart disease (CHD), 49 
heart failure (HF), and atrial fibrillation (AF) (Lavie, McAuley, et al. 2014; Ndumele, Matsushita, et 50 
al., 2016).  51 
Currently, various preventive public health strategies ranging from managing the risk factors, lifestyle 52 
change, physical exercise, and smoking cessation aimed at reducing the incidence of CVD are in 53 
implementation. Several pharmacological drugs such as beta-blockers, angiotensin-converting enzyme 54 
(ACE) inhibitors, statins, and antiplatelet drugs are also commercially available for management of 55 
cardiovascular-related diseases. However, these drugs are not efficient as some of these drugs have 56 
adverse side effects, are costly and the pharmacological efficiencies are constrained by patient non-57 
compliance (Tomé-Carneiro & Visioli, 2016). This has resulted in apparent limitations in effective 58 
therapeutics for CVD, and the search for better treatment strategies and options remains a priority. 59 
Knowledge of underlying mechanisms interrelating obesity and cardiac dysfunction is essential to 60 
identify potential therapeutic targets for cardiovascular dysfunctions. In the last few decades, 61 
significant effort has been made to elucidate the association between obesity and CVD. However, the 62 
biomolecular events and mechanisms governing the development of obesity-related CVD remains 63 
unclear. This has led to a relative paucity of therapeutic measures for the prevention and treatment of 64 
obesity-related CVD and associated metabolic disorders.   65 
Interestingly, numerous in vitro and animal studies have documented the role of ERS in the 66 
pathophysiology of different subtypes of CVD. Recent studies have highlighted the pivotal role of 67 
prolonged ERS-initiated activation of the UPR, and the ensuing chronic low-grade inflammation, and 68 
altered insulin signaling in promoting obesity-compromised CVS (Hotamisligil, 2010; Man Liu & 69 
Dudley, 2015; Szymański, Janikiewicz, et al., 2017; Thorp, 2012;  Zhang, Syed, et al, 2017). However, 70 
the precise mechanism of this phenomena is not clearly understood. Therefore, a thorough 71 
understanding of how obesity causes persistent ERS in the myocardium and triggers provocative 72 
activation of the UPR signaling, inflammation, and insulin resistance is critical.  73 
In the current article, we review the existing knowledge of obesity-linked CVD, ERS, inflammation, 74 
insulin resistance, and oxidative stress in the pathophysiology of obese compromised CVS. 75 
Moreover, we summarize molecular mechanisms of ERS-associated CVDs, highlighting common 76 
interplaying mechanisms which could be of tendency for future novel drug discovery. Furthermore, 77 
our review will discuss current progress in CVDs therapeutics and the roles of phytochemicals and 78 
small molecules as potential therapeutics for the prevention and treatment of CVDs, emphasizing 79 
new directions for studying the pathophysiology of CVDs and for developing novel drugs targeting 80 
ERS and UPR 81 
2 Correlation between obesity and cardiac dysfunction 82 
Obesity is a nutritional disorder which results from an accumulation of body fat in certain parts of the 83 
body in a way that adversely affects health. It often occurs due to an imbalance between dietary 84 
intake and energy expenditure. The association between obesity and CVD is a well-established 85 
phenomenon. Data from experimental, epidemiological, and clinical studies including the 86 
Framingham Heart Study, the Manitoba Study, and the Harvard Public Health Nurses Study (van 87 
Gaal, Mertens, et al. 2006; Poirier, Giles, et al. 2006), support the notion that obesity is an 88 
independent risk factor and leads to adverse cardiometabolic effects. Of significant note, in the 89 
Framingham Heart Study involving the echocardiography (ECG) of healthy and obese individuals, 90 
the latter had increased left ventricular hypertrophy (Siti, Kamsiah, et al. 2015). Moreover, several 91 
experimental and clinical studies have shown the role of excess calories, an underlying problem 92 
leading to obesity, in the development of obesity-associated CVD, including cardiac hypertrophy and 93 
myocardial dysfunction (Guo, Zhang, et al. 2013). The correlation between excess 94 
nutrition/overweight/obesity and other risk factors such as hyperlipidemia, high free fatty acids 95 
(FFAs), reactive oxygen species (ROS), ERS, inflammation, and insulin resistance and cardiac 96 
dysfunction. 97 
3 Role of Endoplasmic reticulum stress (ERS) in CVD 98 
3.1 Endoplasmic reticulum (ER) 99 
The ER is responsible for several cellular homeostatic responses including synthesis and post-100 
translational modifications of secretory, luminal and transmembrane proteins and folding and 101 
maturation of newly synthesized secretory and membrane proteins (Malhotra & Kaufman, 2011). The 102 
ER serves as the primary site for the biosynthesis of nearly 33% to 35% of all cellular proteins 103 
(Glembotski, 2008; Minamino & Kitakaze, 2010). It is also a site for cholesterol/steroid and lipid 104 
biosynthesis and a core site for calcium storage and homeostasis (Liu, Chen, et al., 2016).  105 
The ER has two membrane subdomains, namely rough and smooth ER. While the laminar structured 106 
rough ER is mainly responsible for synthesis, modification, folding, and processing of nascent 107 
polypeptide chains of secreted, transmembrane, and luminal proteins and Ca2+ signaling; the tubular 108 
structured, smooth ER is a central site for lipid biosynthesis and modification as well as Ca2+ signaling 109 
(Luchetti, Crinelli, et al., 2017).  110 
In eukaryotic cells, newly synthesized proteins need to undergo posttranslational modification and 111 
proper folding in the ER lumen, as only correctly folded proteins are routed to the nucleus, Golgi 112 
apparatus, and cytosol. The post-translational modification processes include folding of the protein 113 
into naïve 3D conformation, glycosylation, and disulfide bond formation (Liu, Chen, et al., 2016). 114 
Protein folding is the process by which a linear polymer of amino acids acquires a unique 3D structure 115 
(the native conformation) capable of performing its cellular function. During the folding process, 116 
proteins often interact with molecular chaperones that bind to the hydrophobic regions of unfolded 117 
proteins to facilitate the folding process (Kitakaze & Tsukamoto, 2010). These complex cellular 118 
processes are governed by a highly regulated quality control system within the ER known as the 119 
unfolded protein response (UPR), which is initiated in response to homeostatic de-arrangements which 120 
triggers endoplasmic reticulum stress (ERS). ERS is cellular stress within the ER which was first 121 
described by Kozutsumi when increased production of the 70 kDa glucose-regulated protein (GRP78) 122 
was induced in the presence of misfolded foreign proteins in the cytoplasm (Kozutsumi, Segal, et al., 123 
1988).  124 
Cells are susceptible to a range of environmental stimuli including radiation, hypoxia shock, heat, and 125 
oxidation, nutrient deprivation, energy disturbance, calcium depletion, oxidative stress, (Kitakaze & 126 
Tsukamoto, 2010; Liu, Chen, et al., 2016), and epigenetic alterations such as altered glycosylation, 127 
deoxyribonucleic acid (DNA) damage, DNA methylation and histone modification (Schiano, Vietri, et 128 
al., 2015), which can result in aberrant protein folding. Moreover, tissue-specific stimuli or 129 
pathological conditions can also trigger the ERS. For example, some cardiac pathologies are implicated 130 
to impair secreted and membrane protein folding and disturb the homeostatic balance. The secreted 131 
and transmembrane proteins in the ER play important roles in maintaining myocardial health and 132 
disease (Doroudgar & Glembotski, 2012). 133 
3.2 ERS and the UPR signaling 134 
The UPR is a highly conserved adaptive system found in most eukaryotes and yeast. The UPR is a 135 
component of the ER adaptive system which comprises three principal signaling pathways namely, 136 
inositol-requiring enzyme 1 (IRE1),  PKR-like ER kinase (PERK), and activating transcription factor 137 
6 (ATF6) (Hotamisligil 2010; Zhang, He, et al., 2017; Liu & Dudley, 2014). These UPR sensors have 138 
two terminals, N-terminus located inside the lumen and C-terminus located in the cytosol, forming a 139 
bridge connecting the ER lumen to the cytosol (Minamino & Kitakaze, 2010). In addition, the UPR 140 
adaptive system is mediated by molecular chaperones and luminal enzymes including, the binding 141 
immunoglobulin protein (BiP) such as GRP78 and GRP94, calreticulin, and lectins calnexin including, 142 
protein disulfide isomerase (PDI) and Erp57, thiol-disulfide oxidoreductase (Malhotra & Kaufman, 143 
2011).  144 
Accumulation of misfolded proteins in the cytosol triggers a heat-shock response, which stimulates the 145 
transcription of genes encoding cytosolic chaperones to refold destabilized proteins. At the same time, 146 
accumulation of misfolded proteins in the ER initiates a signaling cascade extending from the ER to 147 
the nucleus that induces a comprehensive gene expression program to increase the protein folding 148 
capacity of the cell according to the physiologic demands (Kitakaze & Tsukamoto, 2010). Likewise, 149 
disturbance in a physiologic function of the ER leads to ERS and triggers activation of the 150 
evolutionarily conserved UPR to compensate for the damage. Thus, following the onset of ERS, the 151 
UPR is triggered and, the three branches, IRE1, PERK, and ATF6 are activated (Lee & Ozcan, 2014; 152 
Thorp, 2012). Furthermore, downstream of the three UPR signaling pathways, transcription factors are 153 
also activated and UPR associated genes are upregulated (Sozen & Ozer, 2017).  154 
When the ERS in the lumen is within the handling capacity of the UPR adaptive mechanism, the UPR 155 
adaptive system is activated, and as a result, the stress is resolved. Activation of the UPR signaling 156 
networks initiates attenuation of the global protein translation, synthesis of folding enzymes, and ER-157 
associated degradation (ERAD). While synthesis of folding enzymes facilitates proper protein folding 158 
activity, attenuation of the global protein translation reduces the folding burden. Similarly, the ERAD 159 
eliminates aggregates of misfolded proteins, and this reduces the unfolded protein load within the 160 
network. As a result, the alterations caused by the ER are corrected and replenished without any further 161 
prolonged effects. However, chronic accumulation of unfolded/misfolded proteins followed by 162 
persistent disruption of the ER lumen may lead to malfunction of the UPR signaling to adapt itself to 163 
the changes caused by unfolded protein aggregates ( Liu, Chen, et al., 2016). Consequently, this leads 164 
to latent apoptotic or necrotic cell death (Xu, Bailly-Maitre, et al., 2005). Many lines of evidence have 165 
reported the role of ERS and initiation of UPR, which in chronic stress, may lead to myocardial 166 
apoptosis, in the pathophysiology of various CVDs including heart failure, atherosclerosis, cardiac 167 
hypertrophy and ischemic heart disease (Minamino & Kitakaze, 2010). ERS-initiated apoptotic cell 168 
death plays a favorable role in the pathophysiology of several chronic diseases including CVD and 169 
T2DM. The adaptive and maladaptive mechanism mediated by the UPR is illustrated in Figure 1. 170 
3.2.1 The three branches of UPR signaling effectors 171 
The three main proximal effectors of UPR ( PERK, IRE1, and ATF6) are activated with different 172 
strengths and at different time courses (Glembotski, 2014) and may act deferentially or synergistically. 173 
These effectors can serve both adaptive and maladaptive roles except for ATF6 which predominantly 174 
plays an adaptive functional role in many of the cell types. All of these sensors exist in an inactive state 175 
through their maintained interaction with GRP78 via their luminal N-terminus.  176 
The ERS is initially mediated by dissociation of GRP78, a signaling molecule which acts as a 177 
multifunctional modulator and determinant for the downstream regulation of UPR signaling ( Liu, 178 
Chen, et al., 2016). Eventually, activated UPR mitigates ER stress by suppressing synthesis of global 179 
proteins, inducing ERAD of unfolded/misfolded protein, and enhancing production of molecular 180 
chaperones which facilitate proper protein folding. Nevertheless, persistent perturbation of the ER 181 
leads to malfunction within the network and chronic failure of the UPR adaptive system.  182 
3.2.1.1 PERK signaling pathway 183 
PERK is a transmembrane protein that activates the UPR signaling pathway and senses 184 
mitochondrial ROS. First identified as a serine/threonine kinase in pancreatic islets of rat (Almanza, 185 
Carlesso, et al., 2019), PERK, is activated following the onset of ER stress and dissociation of the 186 
Bip GRP78 via dimerization and autophosphorylation of the PERK (Li, Guo, et al., 2014). 187 
Dissociation of GRP78 from the luminal domain of PERK and relocation to unfolded proteins in the 188 
ER leads to oligomerization and autophosphorylation of PERK inducing its kinase and 189 
endoribonuclease activity. As a result, eIF2α undergoes phosphorylation, resulting in a decrease in its 190 
translational initiator, which eventually leads to attenuation of cellular mRNA, a phenomenon 191 
characterized by a reduction in global protein biosynthesis collectively known as a translational 192 
arrest. This translational arrest reduces the protein biosynthesis load, thereby maintaining the ER to 193 
its cellular homeostasis and facilitating efficient ER protein folding. 194 
The role of PERK is not limited to the activation of eIF2α/ATF4- mediated apoptotic event via CHOP 195 
but also encompasses ROS detection and ER and mitochondrial tethering (Thoudam, Jeon, et al., 2016). 196 
Following eIF2α phosphorylation, the mRNA that encodes ATF4 is translated more efficiently and 197 
leads to increased expression of ATF4 (Glembotski, 2008). As a result of this, ATF4 is translocated 198 
into the nucleus where it binds to the unfolded protein response element (UPRE), resulting in 199 
transcriptional modification of UPR target genes including the proapoptotic transcription factor, 200 
CHOP. It is noteworthy that the ATF4 transcriptional activity in early stage of ERS induces prosurvival 201 
pathways; whereas in the late phase where ERS prolonged, it initiates the proapoptotic transcriptional 202 
programs through increased expression of the proapoptotic protein CHOP (Groenendyk, 203 
Sreenivasaiah, et al., 2010). If the ERS is restored,  activation of GADD34 (growth arrest and DNA-204 
damage-inducible protein 34) follows and dephosphorylates eIF2α via negative feedback (Basseri & 205 
Austin, 2012), resulting in attenuation of translational repression exerted due to ERS (Figure 2). In 206 
general, phosphorylation of PERK canonical pathways (eIF2α/ATF4-/CHOP) attenuates global 207 
translational process and inhibits transcription of I kappa B alpha (IκBα), leading to hyperactivation of 208 
NFκB. 209 
3.2.1.2 The IRE-1 signaling pathway 210 
The IRE-1 is also a transmembrane protein which encodes a type 1 ER-resident transmembrane protein 211 
and is present as an inactive monomer until it undergoes autophosphorylation and becomes an active 212 
oligomer forming clusters on the ER (Luchetti, Crinelli, et al., 2017). Under normal conditions, the 213 
IRE-1 remains bound to GRP78 in the ER membrane forming an inactive complex. However, when 214 
ER stress is induced, GRP78 is relocated from the ER lumen to rescue unfolded proteins, resulting in 215 
homodimerization and autophosphorylation of IRE-1 (Liu, Chen, et al., 2016). Upon 216 
autophosphorylation, unlike the PERK receptor, IRE-1 exhibits a novel endoribonuclease activity 217 
(Glembotski, 2008), which leads to excision and splicing of its substrate, the 26-nucleotide sequence 218 
XBP1 mRNA. The splicing of XBP1 mRNA which takes place in the cytosol generates a transcript 219 
with a new open reading frame that encodes the expression of an active form of XBP1. This results in 220 
spliced XBP1 protein (sXBP1) with 5’and 3’ mRNA fragments that enhances IRES-dependent 221 
translation of XBP1 mRNA and leads to transactivation of UPR target proteins including CHOP, 222 
XBP1, endoplasmic reticulum oxidoreductin 1 (ERO1), P58IPK, ER degradation-enhancing 223 
αmannosidase-like protein (EDEM), and RAMP-4  (Toth, Nickson, et al., 2007). 224 
The XBP1 mRNA expression is dependent on the activation of the ATF6 receptor protein. 225 
Translocation of the spliced XBP1 mRNA into the nucleus facilitates the upregulation of genes that 226 
are crucial for protein folding and secretion, and ERAD (Basseri & Austin, 2012; Thorp, 2012). 227 
Eventually, the translocated sXBP1  mRNA binds to the promoter region of the ERS response element 228 
(ERSE) I and II (ERSE-I: CCAAT(N9) CCACG; ERSE-II: ATTGG(N1) CCACG) and the mammalian 229 
UPR element (mUPRE: TGACGTGG/A) to regulate a variety of UPR-related genes which are 230 
essential to induce degradation of malfunctioned cells (Luchetti, Crinelli, et al., 2017; Minamino & 231 
Kitakaze, 2010). On the other hand, IRE-1 collaborates with TRAF2 to activate protein kinases that 232 
are associated with inflammatory response and cellular apoptosis, particularly the apoptosis signal-233 
regulating kinase 1 (ASK1) which eventually leads to activation of JNK (Kim, Xu, et al., 2008) (Figure 234 
2). 235 
3.2.1.3 ATF6 signaling pathway  236 
Like PERK and IRE-1, ATF6 is also an ER transmembrane protein, and under ERS conditions, the 237 
GRP78 dissociates from the N-terminus of ATF6 and is recruited to luminal unfolded/misfolded 238 
proteins. In contrast to PERK and IRE-1 UPR signaling effectors which remain associated with the 239 
ER, ATF6 doesn’t undergo oligomerization or autophosphorylation but release of GRP78 from N-240 
terminus of ATF6 triggers a different mechanism of protein activation which leads to the binding of 241 
GRP78 to unfolded proteins within ER. Meanwhile, relocation of GRP78 leads to translocation of 242 
ATF6’s cytosolic fraction to the Golgi apparatus, where it is spliced and proteolyzed by the Golgi 243 
resident site 1 protease (S1P) and site 2 protease (S2P) (Basseri & Austin, 2012). The cleavage of 244 
ATF6 at a juxtamembrane site leads to its release into the cytosol (Xu, Bailly-Maitre, et al., 2005) and 245 
the release of the cytosolic 50KDa soluble fragment of ATF6 which translocate into the nucleus where 246 
it sequesters with the ERRE (Basseri & Austin, 2012; Thorp, 2012), leading to transcriptional 247 
regulation and activation of UPR target genes including XBP1, CHOP, and GRP78/BiP.  248 
The ATF6 transmembrane protein has another isoform known as ATF6β, and other ATF6-related 249 
membrane proteins namely, Oasis, Luman, CREB4, CREB-H, and BBF2H7, all of which are ER 250 
transmembrane proteins that are cleaved and translocated to the nucleus under ERS (Glembotski, 251 
2008). In this context, the ATF6 serves as a transcription factor in the promoter regions of genes 252 
including XBP1, CHOP, and P58IPK (a PERK inhibitory protein via positive feedback). In the heart, 253 
there are two ATF6-inducible genes namely, RCAN1 and Derl3 which are shown to be adaptive and 254 
encode proteins that attenuate increased protein-folding demand and facilitate degradation of unfolded 255 
proteins (Glembotski, 2014). Coordinately, the three arms of the UPR signaling regulate the translation 256 
and transcription of various proteins and genes encoding chaperones and protein folding enzymes, 257 
which alleviates the burden of unfolded/misfolded protein accumulation (Figure 2). 258 
3.3 ERS and inflammation in CVD 259 
3.3.1 Inflammation  260 
The ability of eukaryotic organisms to survive is dependent on their ability to fight and defend 261 
themselves from infectious organisms, heal damage or injury caused and reserve energy for times of 262 
high demand. Inflammatory responses triggered by the collaborated activity of the innate and adaptive 263 
immunity are among such natural defensive systems through which multicellular organisms overcome 264 
infectious agents or deviant environmental stimuli. Metabolic and immune systems are among the 265 
homeostatic components which have evolved to be closely linked and codependent (Wellen & 266 
Hotamisligil, 2005). Thus, the integration of metabolism and immunity determines the maintenance of 267 
a complete immune system and good health. However, under aberrant conditions, for example, in 268 
nutritional excess or poor nutrition, this integration can trigger deleterious health effects.  269 
Inflammation is an adaptive mechanism initiated in response to cell damage caused by endogenous or 270 
exogenous stimuli such as infectious microorganisms, trauma, or chemical agents (Kawasaki, Asada, 271 
et al., 2012). In the normal physiological state, acute inflammation acts as an adaptive system to get 272 
rid of a stimulus. However, chronic inflammation resulting from repeated injury and repair leads to 273 
damage and malfunctions to the tissue. Inflammation is considered a crucial element in the 274 
development and progression of chronic metabolic diseases including diabetes and CVD (Thoudam, 275 
Jeon, et al., 2016). Chronic inflammation of the vascular system is implicated in the pathophysiology 276 
of cardiac dysfunction. CVD is a chronic inflammation of the lining of the blood vessel which results 277 
due to transendothelial infiltration of cholesterol-rich and atherogenic Apo-B lipoproteins from the 278 
plasma into the intima. Consequently, these infiltrated lipoproteins are retained in the sub-endothelia, 279 
facilitating macrophage and T-cell migration and sequestering with one another and cells of the arterial 280 
wall, an event which promotes atherosclerosis (Nakayama & Wang, 2010). 281 
 Unlike the classical inflammation with typical cardinal features such as pain, heat, swelling, and 282 
redness, chronic low-grade inflammation, also known as metabolic inflammation, is a form of 283 
inflammation often triggered by adiposity/obesity (van Diepen, Berbée, et al., 2013). This type of 284 
inflammation is associated with the development of metabolic syndrome including atherosclerosis, 285 
hypertension, and prothrombin (Emanuela, Grazia, et al., 2012) which are risk factors for the 286 
development of T2DM and CVD. Although the mechanism of chronic low-grade inflammation is not 287 
precisely known, the increased translocation of lipopolysaccharide (LPS) or endotoxin from gut to 288 
circulation which causes metabolic endotoxemia is speculated. In addition, animal studies have shown 289 
that diets high in saturated fatty acids and cholesterol activate inflammatory processes in adipose tissue, 290 
liver, and vasculature (van Diepen, Berbée, et al., 2013).  291 
Several studies have documented a strong association between obesity and chronic inflammation. 292 
Chronic low-grade systemic and local inflammation that is triggered in condition of nutritional excess 293 
are implicated in various metabolic disorders including T2DM and CVD. Obesity itself is characterized 294 
by inflammatory response in which crucial mediators of inflammation like TNF-α show significant 295 
patterns of expression in both animal models and humans. In addition, data obtained from 296 
transcriptional profiling studies showed that inflammatory and stress-response genes are highly 297 
upregulated in adipose tissue of obese animals (Wellen & Hotamisligil, 2005).  298 
Continuous deposition of lipids and expansion or hypertrophy of adipose tissue (AT) stimulates 299 
adipose tissue macrophages (ATM) and other infiltrating macrophages to generate excess 300 
inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-), c-Jun N-301 
terminal kinase (c-JNK) and nuclear factor-kappa B (NF-B), resulting in metabolic inflammation 302 
(Chen, Chen, et al., 2015; van Diepen, Berbée, et al., 2013). In addition, the presence of excess ROS 303 
can also trigger oxidation of low-density lipoprotein (LDL), which is taken up by macrophages via 304 
scavenger receptors, leading to the development of atherogenesis (Sozen & Ozer, 2017), a common 305 
feature of CVD.  These events are considered contributing factors for obesity-associated inflammation 306 
in which pro-inflammatory cytokines like TNF-α and IL-6 are increasingly expressed and anti-307 
inflammatory markers such as adiponectin are downregulated. 308 
Pattern-recognition receptors (PRRs) including Toll-like receptors (TLR) and the receptor for 309 
advanced glycation end-products (RAGE) are implicated in the pathophysiology of obesity-related 310 
inflammation and associated complications. The PPRs are components of innate immunity and are 311 
activated in response to aberrant conditions such as over-nutrition. TLRs comprise different 312 
subfamilies which have unique features of sensing pathogens and detecting tissue injury via the specific 313 
pathogen-associated molecular patterns (PAMPs) and the danger-associated molecular patterns 314 
(DAMPs) (Ota, 2014).  315 
3.3.2 ERS-mediated inflammation  316 
As discussed in section 3.2, when ERS is induced, the UPR signaling is activated, resulting in increased 317 
expression of GRP78, and phosphorylation of IRE-1, PERK, and ATF6 signaling receptors. Through 318 
activation of these UPR signaling networks, ERS is resolved.  However, if the UPR adaptive 319 
mechanisms fail to restore the imbalance caused by ERS to a physiologic homeostasis, the IRE-1α-320 
dependent apoptotic signaling pathway, which occurs via diverse pathways, is inevitable. As illustrated 321 
in Figure 3, phosphorylation of IRE-1α leads to TRAF2 recruitment causing activation of downstream 322 
signaling of JNK and NF-κB, leading to the production of proinflammatory cytokines (Liu, Chen, et 323 
al., 2016). Additionally, phosphorylated IRE-1α interacts with a mitogen-activated protein kinase, 324 
ASK1, which eventually phosphorylates JNK (Minamino & Kitakaze, 2010).  325 
As discussed in section 3.2.1.1, PERK phosphorylates eIF2 and downstream signaling of this pathway 326 
upregulates inflammatory genes and increases secretion of proinflammatory proteins including TNF-α 327 
and IL-6 resulting in persistent inflammation.  In parallel, autophosphorylation of PERK initiates 328 
activation of eukaryotic initiation factor 2 (eIF2) which further undergoes phosphorylation and results 329 
in translational attenuation of protein synthesis. This downstream phosphorylation of eIF2 leads to 330 
increased expression of ATF4 and translocation into the nucleus where it binds to the UPRE resulting 331 
in transcriptional modification of CHOP, a proapoptotic gene transcription factor which initiates 332 
inflammation as well as apoptosis. IRE-1 recruits TRAF2 and causes activation of downstream 333 
signaling of kinases including JNK and NF-κB, inducing the production of inflammatory cytokines. 334 
PERK phosphorylates eIF2α, leading to activation of NF-κB and CHOP to further promote the 335 
expression of inflammatory genes (Figure 3).  336 
ERS and activation of the UPR signaling play a crucial role in the development of CVDs. For example, 337 
UPR activation is implicated in ischemic myocardium, cardiac hypertrophy, and heart failure. 338 
Likewise, increased expression of CHOP and caspase 12 is implicated in the progression of cardiac 339 
hypertrophy to heart failure and cardiomyocyte death (Kitakaze & Tsukamoto, 2010).  Many lines of 340 
evidence indicated the important role of ERS in the development and progression of CVDs, but there 341 
remains much to understand the molecular mechanisms of ERS and chronic activation of UPR 342 
signaling pathway in the pathogenesis of CVDs. Although most of the knowledgeable discussed above 343 
are well established in systems other than CVS, much remains to learn the CVS-targeted underlying 344 
molecular mechanisms of ERS-induced CVDs via activation of the UPR signaling pathways.  345 
3.4 ERS and insulin resistance 346 
3.4.1 Insulin resistance  347 
Insulin, secreted by the pancreatic beta cells, is a key regulatory enzyme in carbohydrate-lipid 348 
metabolism. Insulin plays a significant role in maintaining energy balance in a physiological state and 349 
helps decrease circulating blood glucose by increasing cell permeability to monosaccharides, amino 350 
acids, and fatty acids. In addition, insulin facilitates metabolic processes such as glycolysis, the pentose 351 
phosphate cycle, and glycogen synthesis in the liver, which eventually leads to reduced circulating 352 
blood glucose. Metabolic functions of insulin include facilitating glucose infusion into metabolic 353 
tissues, stimulating the synthesis of fatty acids and glycogen, promoting mitochondrial function, 354 
promoting microcirculation and cell proliferation (Ye, 2013). Insulin also helps downregulate essential 355 
gluconeogenic enzymes in the liver, and promotes triglyceride deposition by accelerating glucose 356 
degradation via glycolysis and synthesis of free fatty acids, and inhibits lipolysis in fat cells (Stafeev, 357 
Vorotnikov, et al., 2017).  358 
Activation of the insulin receptor tyrosine kinase, which leads to phosphorylation of insulin receptor 359 
substrate (IRS) on multiple tyrosine residues, is the primary molecular signaling node for insulin action 360 
(Kahn & Flier, 2000). Insulin binds to insulin receptors on the surface of insulin-responsive cells and 361 
stimulates insulin-responsive receptors and other substrates including IRS-1 and IRS-2. Interaction of 362 
insulin to IRS leads to phosphorylation of IRS, thus initiating downstream insulin signaling cascades. 363 
Binding of insulin to its receptor, receptor phosphorylation, tyrosine kinase activity, and 364 
phosphorylation of IRS are reported in both muscle cells and adipocytes (Kahn & Flier, 2000).  In 365 
addition, the insulin-dependent translocation of glucose transporter 4 (GLUT4) in the skeletal muscle 366 
and fat cells and increased expression of glucose transporter 1 (GLUT1) in vascular endothelium cells 367 
play a major role in maintaining the physiological function of insulin (Stafeev, Vorotnikov, et al., 368 
2017). When this physiologic state is perturbed, however, insulin production is impaired and leads to 369 
reduced insulin secretion and elevated blood glucose profile by raising circulating concentrations of 370 
glucose, free fatty acids, and other nutrients. In most cases, such failure is the outcome of direct 371 
impairment in the insulin signaling pathway, mainly due to a disturbance in the IRS and/or 372 
downregulation of the insulin-responsive GLUT4 (Figure 4). These functional defects can have critical 373 
metabolic consequences in glucose homeostasis and lead to reduced cellular responsiveness to insulin 374 
action, thereby resulting in a condition known as insulin resistance (Eckel, Kahn, et al., 2011).  375 
Insulin resistance is characterized by hyperinsulinemia and hyperglycemia, decreased postprandial 376 
glucose infusion rate, high levels of glycosylated hemoglobin (HbA1c), glucose intolerance, 377 
hyperlipidemia, elevated plasma inflammatory markers, and decreased production of adiponectin (Ye, 378 
2013). Insulin resistance is manifested by a decrease in insulin-stimulated glucose transport and by 379 
altered hepatic glucose output, mainly via the IRS/PI-3-kinase/PKB signaling arm. In response to 380 
elevated blood glucose level, pancreatic β-islets tend to produce more insulin to overcome the 381 
disturbance through positive feedback response, favoring a condition known as hyperinsulinemia. 382 
Hyperinsulinemia is a common feature of insulin resistance and T2DM. It is widely accepted that 383 
obesity-induced metabolic perturbations promote insulin resistance and β-cell dysfunction (Eckel, 384 
Kahn, et al., 2011).  Excess abdominal adipose tissue has been shown to release increased FAs which 385 
directly affect insulin signaling. In their review, Qatanani & A.Lazar have described that overweight 386 
people have impaired ability to uptake circulating glucose from the bloodstream into fat and muscle 387 
cells, and to reduce the conversion of glycogen into glucose in the liver leading to elevated blood 388 
glucose level (Qatanani & A.Lazar, 2007). 389 
Several studies have inferred associations between hyperglycemia diabetic cardiomyopathy via 390 
increased supply of free fatty acids (FFAs) to the cardiomyocytes. Johnson et al. hypothesized that 391 
chronically elevated blood glucose level triggers enhanced transportation of FFAs to cardiomyocytes 392 
to a concentration that overwhelms the rate of cellular β-oxidation. This imbalance may lead to 393 
accumulation of triglycerides, triggering lipotoxicity and left ventricular dysfunction (Johnson, Dludla, 394 
et al., 2017). Clearly, the pathophysiology of insulin resistance may include many cellular pathways 395 
such as the inflammatory, neural and endocrine pathways (Qatanani & A.Lazar, 2007) and deregulation 396 
of caloric intake and expenditure in the central nervous system, systemic lipid metabolism, and 397 
perturbation in insulin and glucose signaling in the periphery (Hotamisligil, 2010). However, the 398 
precise molecular mechanisms are subject to further research. 399 
3.4.2 ERS-mediated insulin resistance  400 
Disturbance of immune signaling and ER perturbation are integrating factors influencing metabolic 401 
regulation and emergence of metabolic disease. Infiltration of immune cells and alterations in 402 
inflammatory signaling pathways in adipose tissue are characteristic features in obesity-induced insulin 403 
resistance. Moreover, the ERS and associated perturbation of the immune signaling has long been 404 
documented as critical factors which cause metabolic dysregulation and emergence of metabolic 405 
disease including insulin resistance and CVD (Hotamisligil, 2010).  406 
Studies have shown that obesity-induced ERS results in insulin resistance and T2DM, mainly through 407 
activation of the JNK terminal, a mediator which leads to an alteration in insulin signaling. Several 408 
studies have highlighted this phenomenon in the pathophysiology of obesity-mediated insulin 409 
resistance. According to Wellen & Hotamisligil, cells exposed to one of the proinflammatory 410 
cytokines, TNF-α or high FFAs, have stimulated inhibition of the serine residues of IRS-1, thus barring 411 
downstream insulin signaling/insulin action (Wellen & Hotamisligil, 2005). On the other hand, 412 
following stimuli such as ERS, elevated level of cytokines and high fatty acids, JNK phosphorylates 413 
and associates with the IRS-1 and impairs the sensitivity of the receptor to insulin action (Figure 2 &4). 414 
Low-grade chronic inflammation, also known as metainflammation, is often triggered in response to 415 
an excess nutritional state such as high circulating glucose and saturated fatty acids and is an emerging 416 
mediator of obesity and insulin resistance. Commonly, this type of metabolic inflammation is triggered 417 
via PRR families such as TLRs, inflammasome, RAGE, and nucleotide oligomerization domain (NOD) 418 
activation. TLR2 and TLR4 are highly implicated in obesity-associated inflammation and insulin 419 
resistance as activation of these receptors leads to elevated production of inflammatory cytokines and 420 
recruitment of T-cells and macrophages (Ota, 2014). 421 
Studies have shown that excess nutrition/obesity activates the immune system, specifically innate 422 
immunity through PRRs and leads to recruitment of T-cells and macrophages, subsequently 423 
desensitizing the insulin signaling pathways and leading to the development of insulin resistance, a 424 
precursor of T2DM (Mcfarlane, Banerji, et al., 2001). Adipose tissue macrophages (ATMs) are primary 425 
sources of proinflammatory cytokines such as TNF-α, and IL-6, that suppress insulin action and induce 426 
the development of insulin resistance.  427 
In his seminal article, Hotamisligil, has extensively discussed the role of JNK, particularly the JNK1 428 
isoform, as a central mediator in the pathophysiology of insulin resistance mainly by IRS-1 serine 429 
phosphorylation and subsequent inhibition of insulin actions, through activation of inflammatory 430 
signaling cascades (Hotamisligil & Erbay, 2008; Wellen & Hotamisligil, 2005). IRS-1 and IRS-2 are 431 
essential substrates for the insulin receptor tyrosine kinases (Liang, Chen, et al., 2015) in insulin 432 
signaling pathways. Thus, ablation of the IRS-1/2 receptors by overexpression of inflammatory 433 
molecules suppresses the insulin signaling pathway and results in insulin resistance.  434 
Production of proinflammatory cytokines and suppression of IRS-1 has been documented as a primary 435 
progressive signaling node in the development of insulin resistance. JNK activation and downstream 436 
activation of inflammatory signaling pathways are common features in ERS. Although the complete 437 
mechanism is yet to be elucidated, under ERS, the GRP78/BiP dissociates from the three central 438 
signaling receptors of the UPR including PERK, ATF6, and IRE-1. Phosphorylation of IRE-1α 439 
enhances recruitment of TRAF2, which further activates the c-JNK (Liang, Chen, et al., 2015). In turn, 440 
c-JNK activation triggers increased production of pro-inflammatory markers that are believed to alter 441 
insulin receptor levels and lead to insulin resistance. As illustrated in Figure 2, activated IRE-1 recruits 442 
TRAF2 and this complex causes activation of downstream signaling of kinases including JNK and NF-443 
κB which induces production of inflammatory cytokines. Consequently, IRE-1-mediated JNK 444 
activation disrupts insulin receptor signaling and results in insulin resistance. This is in line with data 445 
from experimental studies conducted on mice wherein significant protection against insulin resistance 446 
and T2DM following JNK1 gene knock out is reported (Hotamisligil & Erbay, 2008). Elevated level 447 
of fatty acids, high blood glucose, ERS, mitochondrial dysfunction, and increased production of 448 
inflammatory cytokines results in increased inhibitory actions of Ser/Thr phosphorylation of IRS-1/2 449 
via activation of JNK, IKK, mTORC1/S6K and MAPK (Boucher, Kleinridders, et al., 2014). ERS 450 
leads to suppression of insulin receptor signaling which leads to diminished insulin signaling through 451 
overactivation of JNK and subsequent serine phosphorylation of IRS-1. Mice deficient in XBP-1 452 
mRNA develop insulin resistance. Upregulation of sXBP-1 mRNA modulates ERS and suppresses 453 
JNK, which enhances insulin signaling indicating the central role of ERS in insulin resistance and 454 
T2DM (Özcan, Cao, et al., 2004). 455 
In studies conducted on heterozygous IKKβ and whole-body JNK1 deficient mice, moderate protection 456 
against high diet-induced insulin resistance was observed (Ota, 2014). This supports the notion that the 457 
IKKβ/NF-κB and JNK pathways are involved in the development of insulin resistance and are 458 
mechanisms that connect inflammation with insulin resistance. Besides, activation of the IKKβ/NFκB 459 
pathway dephosphorylates IRS-1 through increased expression of PTP1B (Zabolotny, Kim, et al., 460 
2008). Akt also has a central role in regulating insulin action. Akt phosphorylates and activates IkB 461 
kinase (IKK), which leads to activation of NF-B (Boucher, Kleinridders, et al., 2014), resulting in 462 
diminished insulin signaling.  463 
Akt is implicated as a central mediator of various insulin actions. Akt mediates insulin actions mainly 464 
by regulating apoptotic and survival proteins, cell cycle regulating proteins and transcription factors. 465 
Among others, Akt phosphorylates Murine double minute 2 (Mdm2), leading to inhibition of p53-466 
mediated apoptosis. The Bax, Bad, and caspase-9 proapoptotic mediators are phosphorylated and 467 
inhibited by promoting cell survival. It also phosphorylates and activates IKK, which leads to activation 468 
of NF-B. Endothelial nitric oxide synthase (eNOS) is also phosphorylated by Akt, thereby enhancing 469 
the production and release of nitric oxide (NO), a prominent vasodilator and anti-inflammatory 470 
molecule (Boucher, Kleinridders, et al., 2014). However, when this physiologic balance is perturbed, 471 
may lead to diminished insulin signaling, resulting in insulin resistance. However, a better 472 
understanding of the etiological factors involved and the complete molecular mechanisms behind 473 
insulin resistance and its association with CVD would inevitably be helpful in the effort to combat 474 
cardiovascular pathologies and T2DM associated comorbidities. 475 
3.5 Oxidative Stress and CVD 476 
Oxidative stress is characterized by overproduction and accumulation of ROS beyond the antioxidant 477 
capacity of living cells to scavenge harmful ROS. In living cells, free radicals, predominantly in the 478 
form of ROS and reactive nitrogen species (RNS) are fundamental biochemical components and are 479 
typical byproducts of cellular metabolic processes (Pavithra & Vadivukkarasi, 2015). Beyond their 480 
physiological roles, however, ROS are also the primary etiological factors and characteristic features 481 
of several chronic diseases including CVD. Interestingly, in the cardiovascular system, ROS acts as 482 
messenger in specific signaling pathways involved in regulating cardiovascular homeostasis 483 
(Cervantes Gracia, Llanas-Cornejo, et al., 2017; Csányi & Miller, 2014). However, the presence of 484 
excess ROS deters pathophysiologic components in several oxidative stress associated diseases such 485 
as cardiovascular diseases (CVD), rheumatoid arthritis, cancers, ulcerative colitis and 486 
neurodegenerative disorders (Pavithra & Vadivukkarasi, 2015).  487 
Several studies have elucidated the effects of ROS induced oxidative stress in CVD and further 488 
demonstrated ROS as a significant contributing factor in the pathogenesis of CVD. Accumulating 489 
evidence indicates a crosstalk between ROS generation and the ERS-initiated UPR activation. Indeed, 490 
studies have shown that although most of the ROS in the ER is generated via Ero1, such redox 491 
imbalance can also be triggered by altered PERK and ATF4 functions which induce genes that facilitate 492 
elimination of ROS (Görlach, Klappa, et al., 2006). Furthermore, the effects of over-accumulation of 493 
ROS is not only confined to inducing oxidative stress in cardiomyocytes but also impairs the 494 
antioxidant system (Liu, Z.W, et al., 2013) which serves as a defense system against free radicals. A 495 
thorough understanding of ROS in the pathophysiology of CVD could lead to new antioxidant-496 
associated therapies.  497 
Under normal physiological balance, damaging effects of free radicals are reversed by enzymatic 498 
antioxidants including superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase, and 499 
non-enzymatic antioxidants such as β-carotene, bilirubin, vitamin E and vitamin C (He & Zuo, 2015). 500 
However, when this naïve protective system is perturbed, an excess of free radicals accumulate, 501 
overriding the antioxidant system and threatening the scavenging efficiency of existing antioxidants, 502 
thus resulting in a condition known as oxidative stress. Such alterations affect crucial cellular events 503 
such as immune cell differentiation, nervous system physiology regulation, stem cell differentiation, 504 
guanylate cyclase activation, and phosphatases, kinases, and growth factor signaling pathways 505 
(Cervantes Gracia, Llanas-Cornejo, et al., 2017).  506 
Several studies have elucidated the effects of ROS induced oxidative stress in CVD and demonstrated 507 
ROS as a significant contributing factor in the pathogenesis of CVD. Although ROS are well known 508 
as critical players in cardiometabolic disorders, the exact mechanisms of how ROS species lead to the 509 
development of CVD is not clearly understood. Nevertheless, emerging studies have shown the role of 510 
ROS in the pathogenesis of different subtypes of CVDs including congestive heart failure, 511 
arteriosclerosis, ischemic heart disease, and xenobiotics-mediated cardiomyopathies via apoptosis 512 
(Ilavenil, Kim, et al., 2015). Furthermore, the presence of excess ROS has oxidation-mediated 513 
damaging effects on cellular macromolecules such as lipids, cell membrane, proteins, and DNA, which 514 
alter cellular function and may contribute to the development of CVD and diabetes (Rajeshwari & 515 
Raja, 2015). Of more interest, studies have shown that in conditions of oxidative stress, nuclear E2-516 
related factor-2 (Nrf2) transcription factor is translocated into the nucleus, and binds to the antioxidant 517 
response element (ARE) through which the gene expressions of enzymatic antioxidant systems 518 
including heme oxygenase-1 (HO-1) and other enzymes involved in glutathione metabolism is 519 
regulated (He & Zuo, 2015). Thus, given the fact that apoptosis is a major causative factor for various 520 
cardiovascular pathologies, correlating apoptosis induced by ROS and ERS might work as a new 521 
perspective approach to elucidate intersecting factors for these two etiologies. 522 
4 Cardiovascular Therapeutics 523 
4.1 Pharmaceutical potentials of phytochemicals in CVD 524 
Plants are the basis of ethnomedicines and have been used as sources of pharmaceuticals for various 525 
ailments for centuries and plants and their derivatives have remained primary sources for lead 526 
compounds for the discovery and development of new therapeutics for several infectious and non-527 
infectious diseases (Odey, Iwara, et al., 2012). Existing reports indicate that nearly 50% of all 528 
therapeutic drugs introduced by pharmaceutical industry are in some ways made from plant-based 529 
active lead compounds (de Oliveir, Tirapelli, et al., 2008). Since medicinal plants are abundant sources 530 
of phytochemicals which have wide ranges of pharmaceutical properties, the research interest and focus 531 
on plant-based bioactive compounds to search for novel medicinal agents and develop potential 532 
therapeutics for various ailments will increase dramatically in the coming decades.  533 
Phytochemicals are bioactive compounds found naturally in plants and their products including 534 
vegetables, fruits, medicinal plants and aromatics, and these plant chemicals are located in different 535 
anatomical parts of plants namely, the leaves, fruits, flowers and roots (R Vasanthi, Shrishrimal, et al., 536 
2012). Phytochemicals are classified as primary and secondary metabolites. While the former serves 537 
as a primary source of energy and has roles in maintaining proper growth and development of plants, 538 
the latter play a role in plant metabolism and defense system against pathogens. Phytochemicals 539 
comprise a range of chemical groups including polyphenols, alkaloids, flavonoids, terpenoids, sterols 540 
and vitamins, each having unique characteristics bioactivity. Owing to their abundant phytochemical 541 
constituents, less adverse effects, and relative cost-effectiveness, plant-derived phytochemicals have 542 
been preferred over synthetic drugs (Azwanida, 2015; Vuddanda, Chakraborty, et al., 2010).  543 
Several compounds with various potential pharmacological activities on different types of CVDs and 544 
their risk factors including anti-oxidant, anti-angiogenic, anti-ischemic, anti-platelet aggregation, anti-545 
inflammatory, anti-hypercholesterolemia, immunosuppressant, and anti-thrombotic activities, have 546 
been identified (Bradamante, Barenghi, et al., 2004; Das & Das, 2007; Pagliaro, Santolamazza, et al., 547 
2015). However, the underlying biomolecular mechanisms of many of these phytochemical 548 
compounds is still incomplete to substantiate their novelty and functionality. In this sense, besides the 549 
efforts and rising interests in plant-based bioactive compounds for the discovery of therapeutics for 550 
CVDs, it is also critically important to give emphasis to unfold useful information on the biological, 551 
toxicological, and structure-activity relationships. One way to achieve this is through employing a 552 
multidisciplinary systematic approach involving in vitro, in vivo, in silico and molecular approaches 553 
to gain more vigorous pharmacological information.  554 
Recent studies have revealed the role of epigenetic alterations including DNA methylation and histone 555 
modification in the progression of CVDs. Interestingly, various plant-based bioactive compounds are 556 
shown to reverse and ameliorate such epigenetic alterations. Resveratrol and curcumin (Table 1) are 557 
among such compounds which have been identified as potential phytochemicals that can modulate 558 
altered epigenetic signaling pathways (Schiano, Vietri, et al., 2015). While resveratrol modulates CVS 559 
related disorders through inhibition of phospholipase A2 COX-2 activity and antagonizing NF-𝜅B, 560 
TNF-𝛼, IL-6, iNOS, MCP-1 (Pagliaro, Santolamazza, et al., 2015), curcumin modulates CVDs through 561 
inhibition of prostaglandin production and NFκB activity, GRP94 induction, and modulation of the 562 
Akt/Nrf2, ERK, MAPK, p38, JNK signaling molecules (Kapakos, Youreva, et al., 2012; Zhang, Gan, 563 
et al., 2015). Abscisic acid (Table 1) has been investigated for its anti-diabetes activity in obesity-564 
related inflammation via PPARγ, NF-κB signaling pathway. Carotenoids (Table 1) have been shown 565 
to modulate obesity-associated inflammation, atherosclerosis, and CVD through ameliorating the IGF-566 
1, IL-1β, IL-6, and MCP-1 signals (Beukes, Levendal, et al., 2014). There are many more 567 
phytochemicals which have been proven to modulate risks of cardiovascular dysfunction and protect 568 
the cardiac system. Given the novelty of some of UPR-associated molecular targets, it is critically 569 
essential to emphasize the use of phytochemicals as sources of potential bioactive compounds to 570 
modulate CVDs resulting from compromised ER, epigenetics mechanisms, environmental factors or 571 
other traditional factors. Some of the best studied phytochemicals in this context, their rich sources, 572 
their biological activities, the mechanisms of action (MOA), and associated molecular targets are 573 
described in Table 1. 574 
4.2 UPR as a potential therapeutic target in CVDs 575 
The ERS and subsequent activation of the UPR have been implicated in the pathogenesis of a number 576 
of CVDs including atherosclerosis, heart failure, and ischemic heart disease (Glembotski, 2014). 577 
Targeting the UPR signaling pathway may be a potential path to modulate different types of CVDs 578 
using pharmacological interventions and to mitigate ERS-associated heart diseases.  579 
4.3 Therapeutic approaches/strategies in UPR-mediated CVDs 580 
There are two approaches to manipulate ERS-activated UPR or utilize the UPR components as 581 
therapeutic targets for the treatment of CVDs. These include activating selective mediators of the UPR 582 
adaptive system and deactivating the ERS-initiated proapoptotic pathway (Minamino, Komuro, et al., 583 
2010). Pharmacological intervention of modulating UPR signaling components can potentially 584 
stimulate an increased capacity to alleviate protein misfolding, with positive therapeutic effects in 585 
cardiac and related metabolic diseases. 586 
Other strategies to utilize the UPR as a target for cardiovascular therapy may include decreasing 587 
misfolded/unfolded proteins, intervening in the activation of the UPR sensors. In particular, selectively 588 
inhibiting the dissociation of GRP78 from the three ERS detectors or inhibiting the activated UPR 589 
sensors and other effectors of the UPR signaling may have efficient therapeutic potential (Man Liu & 590 
Dudley, 2014). While a decrease in misfolded/unfolded proteins reduces the burden caused due to 591 
abnormally deposited unfolded proteins within the lumen of ER, and as a result, leads to elimination 592 
of misfolded proteins, inhibition or attenuation of the UPR sensors or their downstream proximal or 593 
distal effectors including eIF2a/ATF4, ATF6N, and XBP1 with selective inhibitor molecules could 594 
also be a potent approach to mitigate the chronic effects of UPR activation. As illustrated in Table 3, 595 
apelin-13 is reported to have protective effects against I/R injury through inhibition of ERS-mediated 596 
apoptosis and the PERK/CHOP canonical UPR signaling pathway (Liu, Chen, et al., 2016).   597 
Increased expression of chaperone protein GRP78 is central to the recognition of unfolded/misfolded 598 
proteins and the coordinated activation of the UPR signaling (Toth, Nickson, et al., 2007).  At steady-599 
state, GRP78 remains bound to the luminal domain of the three ERS sensors. However, due to its high 600 
affinity towards misfolded/unfolded proteins, GRP78 dissociates from the three sensors and binds to 601 
unfolded/misfolded proteins when ERS is induced. Clearly, targeting GRP78, which is a determinant 602 
in the initiation and progression of ERS-initiated UPR signaling process, could be a useful therapeutic 603 
approach in CVDs.  604 
Several phytochemicals and small molecules have been investigated and identified for their modulating 605 
effect against GRP78 and downstream signaling. Bisoprolol (Table 2&3), for example, has been 606 
reported to attenuate the UPR signaling pathway through suppression of TNF-α and IL-6 secretion, 607 
which consequently down-regulates the PERK/ATF4/eIF2α signaling in myocardial I/R 608 
(ischemia/reperfusion) injury (Zhang, He, et al., 2017). Likewise, Notoginsenoside R1 (Table 2) is 609 
indicated to suppress GRP78, phosphorylated PERK, ATF6, IRE1, CHOP, and phosphorylated JNK 610 
(Liu, Chen, et al., 2016). There are several other compounds which have been discovered for their 611 
potential in mediating the GRP78 downstream pathways in cardiovascular-related pathologies. For 612 
example, Salubrinal93 (Table 2) prevents cardiac hypertrophy, one of the underlying pathophysiology 613 
of cardiac dysfunction and hypertension, a prominent risk factor of cardiac pathologies, through 614 
dephosphorylation of eIF2 (Minamino, Komuro, et al., 2010). Metoprolol and propranolol (Table 615 
1&3), β adrenergic receptor (β-AR) blockers were also tested and modulated heart failure caused by 616 
cardiac hypertrophy in rats. Metoprolol and propranolol exerted this effect via downregulation of 617 
GRP78, XBP-1, and calmodulin kinase II (CaMKII), and CHOP leading to alleviation of ERS and 618 
ERS-induced apoptosis ( Liu, Chen, et al., 2016). 619 
Apoptosis of cardiomyocytes has been reported in various diseases of the cardiovascular system 620 
including myocardial ischemia, heart failure, atherosclerosis, and DCMP ( Lee, & Gustafsson, 2009). 621 
PUMA has recently been identified as critical proapoptotic pathway mediators and important 622 
contributors in the pathophysiology of CVDs including I/R injury. PUMA is a critical contributor in 623 
ERS-induced apoptosis in cardiomyocytes, a novel proapoptotic effector upstream of Bax/Bak, and 624 
sequesters the pro-survival Bcl-2 family. This makes it an appealing therapeutic target for 625 
pharmacological intervention to attenuate myocyte apoptosis in CVD. In light of this, a study has 626 
demonstrated that ERS elicited by thapsigargin or tunicamycin led to upregulation of PUMA in 627 
cultured cardiac myocytes. Importantly, following PUMA-targeted suppression using small molecule 628 
shRNA, the cardiomyocytes managed to recover from ERS-induced cell death; ablation of PUMA has 629 
also reduced heart infarct size and attenuated apoptosis in I/R injury (Toth, Nickson, et al., 2007). 630 
Trigonelline (Table 2) is another candidate compound which is identified as having antiapoptotic effect 631 
against H2O2 induced necrosis and apoptosis in cardiomyocytes via inhibition of proapoptotic 632 
caspases and up-regulation of the distal antiapoptotic Bcl-2 (Ilavenil, Kim, et al., 2015). However, 633 
besides their anti-apoptotic activity, there is a concern over some of these caspase inhibitors as some 634 
have been reported to induce cell necrosis (Ni, Mcgill, et al., 2016). Thus, caution is needed in targeting 635 
selected ERS markers to minimize deleterious effects.  636 
Studies have shown that CHOP mediates the transcriptional repression and activation of proteins from 637 
Bcl-2 family (Minamino & Kitakaze, 2010). Suppression of the pro-survival protein Bcl-2 by CHOP 638 
may be a possible mechanism in CHOP-induced cellular apoptosis (Li, Guo, et al., 2014). Hence, 639 
targeting this proapoptotic protein could be envisioned as a potential strategy for pharmacological 640 
intervention. Metformin is well-studied for its cardioprotective effects in both cardiomyocytes and 641 
rodents. As described in Table 2 & 3, Metformin exerts cardioprotective effects through several 642 
mechanisms including selective activation of PERK-ATF4 UPR arm, and upregulation of CHOP 643 
mRNA and protein (Quentin, Steinmetz, et al., 2012). Berberine is a natural compound with potent 644 
modulatory effects in CVS pathologies. Berberine modulates myocardial I/R injury in rats and cell line 645 
models through activation of AK2/STAT3 and JAK2/STAT3 signaling pathway, attenuation of ERS-646 
induced apoptosis, down-regulation of the phosphorylation levels of myocardial PERK and eIF2α, and 647 
expression of ATF4 and CHOP (Zhao, Yu, et al., 2016). (Table 2 & 3) 648 
The IRE1-α-dependent apoptotic signaling occurs via diverse pathways. Among others, the IRE1-α 649 
interacts with the adaptor protein TRAF2. IRE1α and TRAF2 interact with a mitogen-activated protein 650 
kinase ASK1, which subsequently phosphorylates JNK. Indeed, this pathway is one of the main 651 
pathways which triggers myocyte apoptosis which may lead to various cardiovascular pathologies and 652 
chronic inflammation. Perhaps strategies to inhibit the IRE1-α/TRAF2 interaction, which would likely 653 
block the proapoptotic Ask1/JNK branch, could also be a viable therapeutic approach. Rapamycin is 654 
another compound with the potential of modulating ERS-initiated UPR activation. One way through 655 
which this compound ameliorates ER stress-induced pathologies such as insulin resistance, apoptosis, 656 
adipocyte dysfunction, which are implicated in cardiac dysfunction is through inhibition of mTOR 657 
(mammalian target of rapamycin) (Table 2) (Jung & Choi 2016). In addition, rapamycin suppresses 658 
IRE-1-JNK signaling pathway, which leads to chronic inflammation and altered insulin signaling. 659 
Other studies have also demonstrated the potential of caspase inhibitors in modulating apoptosis. For 660 
example, bisoprolol is implicated in myocardial I/R injury through downregulation of caspase-12 and 661 
3, leading to downregulation of the PERK/ATF4/ eIF2α UPR signaling pathway (Zhang, He, et al., 662 
2017). 663 
In general, inhibition of UPR signaling seems a promising direction in the discovery of novel 664 
therapeutics for CVDs. Many encouraging preclinical studies (in vitro and in vivo) have been 665 
conducted, but gaps and limitations remain in understanding many underpinning scenarios. For 666 
example, it is clearly understood that under normal circumstances, activation of the UPR has a 667 
protective or adaptive role, but chronic activation will have deleterious effects. Unlike acute 668 
interventions which could be undertaken with acceptable risks of side effects, Kim et al. have discussed 669 
in their review that prolonged perturbation of the ERS-initiated UPR signaling in a broad systemic 670 
manner could potentially have indiscriminate deleterious effects on some tissues and organs (Kim, Xu, 671 
et al., 2008). This necessitates the need for a critical time point and temporary therapeutic strategies in 672 
targeting the UPR for therapeutic intervention. Perhaps a specific approach to assess which of the three 673 
ERS signaling arms and associated mediators are activated in response to ERS inducing stimuli would 674 
be very helpful to develop a better strategy for UPR targeted therapeutics. According to Ni et al., TNF-675 
α targeted inhibition of caspases using inhibitor molecule, ZVAD-fmk has shown inhibitory effect 676 
against apoptosis at early intervention but promoted cell necrosis in prolonged treatment (Ni, Mcgill, 677 
et al., 2016). This effect has been observed in both in vitro and in vivo models, raising concern over 678 
the safety of emerging caspase inhibitors which are undergoing clinical trials. As such, caution is 679 
needed in targeting selected ERS markers to minimize deleterious effects. This necessitates the need 680 
for further investigation to elucidate how and when cells decide to enter necrotic or apoptotic pathways 681 
as well as the cross-talk between different cell death mechanisms. 682 
4.3.1 Therapeutics under clinical trials targeting ERS and UPR 683 
The past decade has seen fast developments in therapeutic approaches to treat various metabolic 684 
disorders including high lipid-induced insulin resistance and T2DM.  Some of the potential agents 685 
targeting ER pathway could possibly evolve as effective strategies for obesity-associated 686 
complications. Tauroursodeoxycholic acid (TUDCA) and sodium phenylbutyrate (PBA) (Table 4) 687 
are some of the drugs which have been investigated for their therapeutic effects in obese people who 688 
have lipid-associated insulin resistance. The pharmacological effects and the mechanism of action 689 
(MOA) of these drugs have been linked to a decrease in ERS (NCT00771901 & NCT02344186). 690 
According to the investigation, TUDCA and PBA modulate obesity-related insulin resistance by 691 
reverting ERS and associated biomarkers, thus improve insulin action (NCT00771901). Liraglutide 692 
(Table 4) is another pharmacological drug which was found to ameliorate ER stress and adipose 693 
tissue in obese people who have T2DM (NCT02344186). Alpha-Lipoic Acid (ALA) (Table 4) is a 694 
natural compound which is a potent antioxidant and free radical scavenger with attractive 695 
pharmacological activity for the treatment of T2DM. This compound has undergone phase-4 clinical 696 
trials and its pharmacological effects have been linked to modulation of the insulin signal pathways 697 
and antagonizing the oxidative and inflammatory stresses (NCT01056497). All these findings 698 
implicate the significant of targeting ERS and associated pathways for pharmacological intervention 699 
of common metabolic disorders including insulin resistance, T2DM, and CVD. 700 
4.4 Challenges and future perspectives 701 
As discussed earlier, ERS and associated cellular events, mainly ERS-induced myocyte apoptosis, 702 
have been implicated in the initiation and progression of different types of CVDs. In line with this, 703 
alleviation of ERS and its constituents has recently emerged as a potential therapeutic target to 704 
intervene in CVDs such as heart failure, hypertension, and atherosclerosis (Zhang, He, et al., 2017). 705 
Given that myocyte apoptosis is one of the major contributors to CVDs, perhaps pathways involved 706 
in this event offer an attractive therapeutic target to combat the diseases. In their review, Toth et al. 707 
highlighted that the ERS pathway and mediating molecules which govern cell survival and cell death 708 
are the best targets for pharmacological intervention. However, there are multiple downstream 709 
pathways which lead to proapoptotic events in ERS, as a result, therapeutic strategies targeting or 710 
modulating a single apoptotic pathway may not be enough to preserve the survival of cardiomyocytes 711 
(Kim, Xu, et al., 2008; Xu, Bailly-Maitre, et al., 2005). A deep understanding of the interconnecting 712 
pathways involved in ER-initiated cell death is essential to fully validate targets for drug discovery.  713 
Most of the components of UPR signaling, including the proapoptotic pathway, are widely expressed, 714 
thus blocking their activity may trigger unpredictable adverse effects. This is particularly true in 715 
conditions where delivery of the ligand to the target cell types or tissue fails. Hence, further research 716 
in ERS is needed to elucidate the best therapeutic targets within the various interconnecting 717 
networks. Moreover, molecular mechanisms of ERS-linked proteins and genes regulation involved in 718 
the initiation and progression of ERS-induced cell death are essential for identification of novel 719 
molecular markers for future drug discovery. 720 
5 CONCLUDING REMARKS 721 
CVDs constitute a major challenge and are at an epidemic proportion worldwide. Despite significant 722 
progress made thus far, the development of novel and effective therapeutics for CVDs has continued 723 
to be a major research goal due to limitations and reported side effects in existing therapies. The 724 
impact of ERS-induced activation of UPR signaling in the pathophysiology of CVDs is well 725 
documented in numerous in vitro and animal studies. The apoptotic event which is triggered 726 
following chronic ERS has been implicated in the development and progression of CVDs. 727 
Nevertheless, further research is warranted to identify the best drug targets within the ERS pathway 728 
to expedite the fight against cardiovascular and other metabolic diseases.  729 
ERS pathways may offer attractive targets to combat cardiovascular pathologies and discover 730 
therapeutic alternatives in disease processes. However, there are still many constraints in terms of 731 
understanding the molecular mechanisms of this phenomenon. As such, understanding the underlying 732 
molecular mechanisms of events including the stress-associated UPR activation and ERS-induced 733 
apoptosis resulting from protracted ERS, is of paramount importance. This will lead to gain of 734 
substantial biomolecular information which will help in identifying novel targets for the discovery of 735 
new therapeutic approaches and the development of effective drugs. Therefore, a better and improved 736 
understanding of the molecular mechanisms underpinning activation of UPR and the ensuing cellular 737 
apoptosis in CVD will provide us with new and novel biological targets which can be utilized for 738 
potential therapeutic interventions, and drug discovery for CVDs. 739 
Meanwhile, owing to their immense health benefits, fewer side effects, and a broad spectrum of 740 
pharmacological potentials against different ailments, phytochemicals have become the primary 741 
focus in the discovery and development of therapeutics for a range of diseases including CVD. As 742 
described in Table 1, 2 and 3 several promising compounds that modulate CVDs and protect CVS by 743 
interfering with ERS and UPR signaling and associated mediator molecules have been identified. 744 
Thus, given the significant role of phytochemicals as potential bioactive compounds to modulate 745 
CVDs resulting from compromises in epigenetics mechanisms or other traditional risk factors, it is a 746 
better alternative and perhaps a promising avenue to emphasize the research on such and other 747 
bioactive compounds with multidisciplinary approaches to foster the ongoing efforts to develop novel 748 
drugs and better therapeutic approaches for CVDs. 749 
Figure 1 Adaptive and maladaptive mechanisms of UPR signaling.   750 
Following the onset of ERS in the cardiac system, cardiac-specific UPR is activated and, the three branches of signaling 751 
transducers, PERK, IRE1, and ATF6 are activated. Furthermore, downstream of the three UPR signaling pathways, 752 
transcription factors are also activated and unfolded protein response (UPR) associated genes are upregulated. In general, 753 
activation of the UPR signaling networks initiates attenuation of the global protein translation, synthesis of folding 754 
chaperones and enzymes, and ERAD of misfolded/unfolded proteins in the ER lumen. Thus, through coordinated 755 
attenuation of global protein synthesis, upregulation of ER-resident chaperones and activation of ERAD, the UPR often 756 
manages to resolve/restore acute homeostasis imbalances caused by various stimuli, thus the cells survive (adaptive 757 
mechanism). The primary goal of the UPR activation is to avoid damages caused by the ERS through its adaptive functional 758 
role which reestablish the ER homeostasis, enhancing cell survival. However. intense ERS succumb the cells to apoptosis 759 
death. (maladaptive mechanism). Ones the ERS turns out to be persistent, transcription factors including CHOP, JNK and 760 
caspases are activated, and members of the Bcl family such as Bcl-2 are suppressed, thereby eliciting programmed cell 761 
death. 762 
Figure 2 A schematic representation of downstream effectors, target genes, and possible outcome 763 
in the ERS-activated UPR.  764 
Under ERS, dissociation of GRP78 from its luminal domain leads to oligomerization and autophosphorylation of PERK 765 
ensuing its kinase and endoribonuclease activity. As a result, the α subunit of eukaryotic initiation factor 2 (eIF2) undergoes 766 
phosphorylation, resulting in translational attenuation characterized by a reduction in protein biosynthesis. Parallelly, this 767 
downstream phosphorylation of eIF2 leads to increased expression of ATF4 and translocation into the nucleus where it 768 
binds to the UPR element (UPRE) resulting in transcriptional modification of UPR target genes including the proapoptotic 769 
transcription factor, C homologous protein (CHOP), GRP78, GRP94, and GADD34. While attenuating global 770 
translational process but PERK phosphorylation also inhibits transcription of I kappa B alpha (IκBα), leading to 771 
hyperactivation of NFκB and increased production of inflammatory cytokines (Figure 4.). On the other hand, ERS leads to 772 
autophosphorylation of IRE-1, leading to excision and splicing of its substrate, XBP1 mRNA. Consequently, this results in 773 
spliced XBP1 protein (sXBP1) which translocate into the nucleus, and this will upregulate genes for protein folding enzymes 774 
secretion and ER-associated protein degradation (ERAD). Noteworthy, the ATF6 is activated following PERK and prior 775 
to IRE1 The GRP78 dissociates from ATF6 and recruited to luminal protein aggregates resulting in translocation of ATF6’s 776 
cytosolic fraction to the Golgi where it is spliced and proteolyzed by site one proteases (S1P) and site two proteases (S2P). 777 
Eventually, this leads to the release of the cytosolic domain of ATF6 and entry into the nucleus where it sequesters with the 778 
ERS response element (ERSE) resulting in the activation of UPR target genes including XBP1, CHOP, and GRP78/BiP, 779 
GRP94, PDI. However, chronic ERS which may result from persistent perturbation of the ER can lead to malfunction 780 
within the network and failure of the UPR adaptive system. And as a result, the PERK-mediated post-translational 781 
attenuation is inhibited and further accumulations of unfolded protein aggregates, leading to initiation of C homologous 782 
protein (CHOP) mediated apoptotic deaths of the cells. 783 
Figure 3 Endoplasmic reticulum (ER) stress-mediated inflammation.  784 
Under ERS condition, the UPR is activated, and this leads to activation of the three principal UPR signaling 785 
transmembrane receptor proteins including IRE-1, PERK, and ATF6. Activation of the IRE-1 leads to the splicing of the 786 
mRNA of a transcription factor XBP1 and subsequent expression of a sXPB1, a highly active transcription factor for the 787 
release of ER-resident enzymes and molecular chaperones. As a result, it leads to activation of NF-κB and CHOP resulting 788 
in increased expression of proinflammatory gene products. Likewise, activated IRE-1 recruits TRAF2 and this complex 789 
causes activation of downstream signaling of kinases including JNK and NF-κB which induces production of inflammatory 790 
cytokines which trigger inflammation. These inflammatory kinases then phosphorylate and activate downstream mediators 791 
of inflammation. Phosphorylation of PERK/ eIF2a downstream signaling pathway results in uncoupling of NF-kB from 792 
IkB. As a result, NF-kB translocates into the nucleus where it activates expression of genes encoding proinflammatory 793 
cytokines including IL-1, IL-6, and TNF-a., resulting in persistent inflammatory response.  On the other hands, 794 
autophosphorylation of PERK initiates activation of eukaryotic initiation factor 2 (eIF2) which further undergoes 795 
phosphorylation resulting in translational attenuation of protein synthesis. Similarly, this downstream phosphorylation of 796 
eIF2 leads to increased expression of ATF4 and translocation into the nucleus where it binds to the UPRE resulting in 797 
transcriptional modification of CHOP, a proapoptotic gene transcription factor which initiates inflammation as well as 798 
apoptosis. IRE-1 recruits TRAF2 and causes activation of downstream signaling of kinases including JNK and NFκB, 799 
inducing the production of inflammatory cytokines. PERK phosphorylates eIF2α, which leads to the activation of NF-κB 800 
and CHOP to further promote the expression of the inflammatory gene. ERS leads to dissociation of TRAF from TRAF2-801 
procaspase 12 complex which is located on ER membrane, leads to activation of caspase 12. At the same time, IRE1-JNK 802 
complex recruits TRAF2 leading to the formation of the IRE1-JNK-TRAF2 complex. The ATF6 pathway also activates NF-803 
kB further intensifying the expression of inflammatory genes which secrete more cytokines. 804 
Figure 4 ERS-mediated insulin resistance 805 
 806 
Following the onset of  ERS, the GRP78 BiP dissociates from the three central signaling receptors of the UPR (PERK, 807 
ATF6, and IRE-1). On one hand, IRE1-JNK complex recruits TRAF2 leading to the formation of the IRE1-JNKTRAF2 808 
complex. The IRE1-JNK-TRAF2 complex has an effect on ASK1 activation, which may induce JNK phosphorylation, 809 
ultimately leading to ablation in insulin receptors and results in insulin resistance. Activated IRE-1 recruits TRAF2 and 810 
this complex causes activation of downstream signaling of kinases including JNK and NF-κB which induces production of 811 
inflammatory cytokines which trigger inflammation. These inflammatory kinases then phosphorylate and activate 812 
downstream mediators of inflammation. Consequently, IRE-1-mediated JNK activation disrupts insulin receptor signaling 813 
and results in insulin resistance. Phosphorylation of one of these arms namely, the IRE1α enhances recruitment of TRAF2  814 
which further activates the c-JNK. In turn, c-JNK activation triggers increased production of proinflammatory markers 815 
which are believed to alter insulin receptor and leads to insulin resistance. On the other hand, phosphorylation of IRE-1α 816 
fosters phosphorylation of IRS-1 through JNK-dependent serine and thus inhibits insulin receptor signaling.  817 
6 Tables 818 
Table 1 Plant-based CVD therapeutics, their pharmacological activities, mode of actions, and molecular targets. 819 
Compound/ Class of 
Phytochemical 
Natural sources Pharmacological activities Mechanism of actions (MOA) Molecular targets References 
Resveratrol/ 
Polyphenolic compound 
Polygonum 
cuspidatum, grapes, 
peanuts, and berries 
 Inhibition of lipid peroxidation 
 Free radical scavenging 
 Inhibition of platelet aggregation 
 Anti-inflammatory activity 
 Vasorelaxation activity 
 Modulation of lipid metabolism 
 Increases the expression of NO synthase 
 Decreases the expression of vasoconstrictor ET 
 Inhibits stress-induced ET-1 gene expression 
 Alteration of eicosanoid synthesis 
 Attenuation of arachidonic acid and prostaglandin 
E2 synthesis. 
 Inhibition of phospholipase A2 and COX-2 activity 
 Antagonizes NF-𝜅B, TNF-𝛼, IL-6, iNOS, MCP-1 
AMPK, SIRT-1 pathway, 
NF-𝜅B, TNF-𝛼, IL-6, iNOS, 
MCP-1 
(Pagliaro et al. 
2015; Das & 
Das 2007; 
Bradamante et 
al. 2004) 
Carotenoids 
 
 
Rosa arvensis, Bibes 
nigrum, Fagus 
sylvatica, Malus 
domestica 
Obesity-associated Inflammation, 
atherosclerosis, cardiovascular 
disease 
…………………………. IGF-1, IL-1β, IL-6, MCP-1 
 
(Beukes et al. 
2014) 
Brassica oleracea/ Broccoli, cauliflowers, 
Brussel sprouts, and 
kale 
 Antioxidant 
 Anti-inflammatory 
 Antithrombotic effects. 
……………………………………. Nrf2, MAPK, JNK, Akt, PKB, 
AMPK, SIRT-1, PPAR𝛼, UCP2 
(Pagliaro et al. 
2015) 
Naringenin/Flavonoids 
 
Grapefruit and orange 
 Antioxidant activity 
 Protects LDL Oxidation 
 Increases the activity of antioxidant enzymes and 
non-enzymatic antioxidants 
 Inhibits generation of free radicals 
LOX and COX pathways (Vasanthi et al. 
2012) 
Curcumin/Phenolic 
compound 
Turmeric (Curcuma 
Longa) 
 Anti-inflammatory, antiplatelet, 
antioxidant activity 
 Inhibition of prostaglandin production and NFκB 
activity, an increase of cytokine production 
 GRP94 induction 
JAK2/STAT3, AMPK/UCP2, 
Akt/Nrf2, ERK, MAPK p38, 
JNK, ICAM-1, MCP-1, and IL-8 
(Kapakos et al. 
2012; Zhang et 
al. 2015) 
Isoflavones/ Polyphenols Soybeans, fruits, 
vegetables, legumes, 
herbs, spices, stems, 
Flowers 
 Free radical scavenging and 
antioxidant activity 
 Anti-inflammatory activity 
 Inhibition of eicosanoid generating enzymes 
 Modulation of the production of pro-inflammatory 
cytokines 
ERs, Nrf1, iNO, COX-2, TNF-
α, ICAM-1, VCAM-1, E-
selectin, MCP-1, ERE, CVD ion 
channels, inhibiting calcium 
channels or activating potassium 
channels 
(Guillamo et 
al. 2009) 
(Scholz et al. 
2010) 
Catechin/ Green tea, apples, 
cocoa, and berries 
 Antioxidant, Anti-hypertensive, 
Anti-inflammatory, Anti-
proliferative, Anti-thrombogenic, 
Hypocholesterolemia effects 
 Up-regulation of proinflammatory molecules by 
suppression of NF-kB activity 
 Modulation of cholesterol metabolism 
 (Vasanthi et al. 
2012) 
Quercetin/ Flavonoid Onions, apples, and 
tea/ 
 Anti-thrombogenic 
 Antioxidant 
 Anti-platelet aggregation 
 Decreases superoxide production 
 
 Inhibition of phospholipase A2 activity 
 Inhibition of MAP kinase activation 
 Decreases platelet aggregation and increases 
platelet-derived nitric oxide release 
 Inhibition of phospholipase A2 activity 
 Blockage of the LOX and COX pathways 
LOX and COX pathways, NF-
kB gene 
(Vasanthi et al. 
2012) 
Geraniol Citrus spp. 
 Improve insulin resistance, 
Suppresses, HMG-CoA) 
reductase activity, hepatoma, 
melanoma, and leukemia cells 
………………………. 
PPAR ᵧ (Beukes et al. 
2014) 
Berberine/Alkaloid Hydrastis Canadensis 
 Anti-oxidant, anti-inflammatory 
 Antihyperlipidemic activity 
 Antihypertensive activity 
 Upregulation of SOD and UCP2 
 Downregulation of NADPH oxidase expression 
 Attenuation of ER stress-induced apoptosis 
 Activation of the Nrf2 pathway 
JAK2/STAT3 signaling 
pathway, UPR signaling 
pathway, Nrf2 pathway, 
AK2/STAT3 signaling 
pathway, C-AMPK and 
MAPK/ERK pathway, NFκB 
signaling pathway 
(Pagliaro et 
al. 2015; 
Vuddanda et 
al. 2010) 
Abscisic acid 
Rosa arvensis, Bibes 
nigrum, Fagus 
sylvatica, Malus 
domestica 
 Diabetes, obesity-related 
inflammation 
…………………….. 
PPARγ, NF-κB (Beukes et 
al. 2014) 
Sulforaphane/ Broccoli, cauliflowers, 
Brussel sprouts, and 
kale 
 Antioxidant activities 
 Anti-inflammatory activities 
 Inhibition of angiogenesis 
 Inhibition of phase I enzymes and DNA adducts 
 Induction of phase II antioxidant detoxifying 
enzyme, 
 Induction of cell cycle arrest 
 Expression of Nrf2 
 Nrf2-dependent phase 2 enzymes activation 
 Expression of detoxification enzymes Antioxidant 
Response Elements (ARE) 
 Reduction of VCAM-1 synthesis 
VCAM-1, Nrf2, ARE (Pagliaro et al. 
2015) 
  820 
 821 
Table 2 Preclinical therapeutics (natural compounds, small molecules or peptides) targeting the UPR signaling pathway (In vitro). 822 
Compound Experimental model Disease model Therapeutic activity/Target Indication References 
Berberine H9c2 cardiomyocyte Myocardial ischemia/reperfusion 
(MI/R) injury 
Activation of AK2/STAT3 signaling pathway 
and JAK2/STAT3 signaling pathway, 
attenuation of ERS-induced apoptosis 
Down-regulation of the 
phosphorylation levels of myocardial 
PERK and eIF2α, expression of 
ATF4 and CHOP in heart tissues 
(Zhao et al. 
2016) 
Bisoprolol H9c2 cardiomyocyte Myocardial ischemia/reperfusion 
(I/R) injury 
Inhibition of UPR signaling pathways, 
suppression of TNF-α and IL-6 secretion, 
downregulation of caspase-12 and caspase-3 
expressions 
Attenuation of UPR signaling 
pathway, down-regulation of 
PERK/ATF4/ eIF2α 
(Chengcheng 
Zhang et al. 
2017) 
AG1478 and 542 (Small-
molecule EGFR inhibitors) 
H9c2 cardiomyocyte  Hyperlipidemia/obesity-induced 
cardiac injuries 
Downregulation of TLR4/c-Src, suppression 
of TNFα and IL-6 expression 
Reduction of cardiac inflammatory 
injuries and apoptosis 
(Li et al. 
2016) 
Adiponectin U0126 
(ERK1/2 inhibitor) 
H9c2 cardiomyocyte 
 
Palmitate-induced apoptosis, 
Lipotoxicity-induced 
cardiomyopathy 
Caspase-3 and PARP activity inhibition, 
ERK1/2 signaling pathway, inhibition of the 
Akt signaling pathway 
Increase the protein level of 
PI3K/Akt and decrease the protein 
level of ERK1/2 
(Wei et al. 
2012) 
Trigonelline H9c2 cardiomyocyte 
 
H2O2-induced H9c2 cell deaths, 
oxidative stress-mediated CVD 
Down-regulation of proapoptotic caspase-3 
and caspase-9, up-regulation of Bcl-2 and Bcl-
XL expression. 
H2O2 induced necrosis and apoptosis (Ilavenil et al. 
2015) 
Elatoside C  H9c2 cardiomyocytes -------------- Upregulation of p-STAT3, and 
downregulation of CHOP, GRP78, JNK 
Suppression of ER stress (H. Liu et al. 
2016) 
D942 (Small molecule) and 
curcumin (Combination 
treatment) 
Primary cardiomyocyte Myocardial ischemia/reperfusion 
(I/R) injury 
Activating AMPK pathway or inhibiting 
mTOR signaling  
Upregulates autophagy and promotes 
cell survival 
(Yang et al. 
2013) 
Metformin Primary rat 
cardiomyocytes 
N/A Selective activation of PERK-ATF4 UPR arm, 
Upregulation of CHOP mRNA and protein 
Cardioprotective effect (Quentin et al. 
2012) 
Rapamycin L6 myotubes Diabetic cardiomyopathy 
(DCM) 
Inhibition of mTOR (mammalian target of 
rapamycin), selective suppression of the IRE1-
JNK signaling pathway, restoration of 
hyperlipidemia-induced ER stress/NFκB-
mediated pathway 
Ameliorates ER stress-induced 
insulin resistance attenuated ER 
stress-induced apoptosis, ameliorates 
adipocyte dysfunction, upregulates 
autophagy 
(Jung & Choi 
2016) 
Notoginsenoside R1 H9c2 cardiomyocytes ---------------- Suppression of GRP78, p-PERK, ATF6, 
IRE1, CHOP, p-JNK 
----------------- (H. Liu et al. 
2016) 
Salubrinal93   Cardiac hypertrophy and 
hypertension 
Prevention of eIF2a dephosphorylation  (Minamino et 
al. 2010) 
 823 
Table 3 Preclinical therapeutics (natural compounds, small molecules or peptides) targeting the UPR signaling pathway (In vivo). 824 
Compound Experimental model Target disease Therapeutic activity /Target Indication References 
Berberine 
 
Male Sprague-Dawley 
rats 
Myocardial ischemia/reperfusion 
(I/R) injury 
Activation of AK2/STAT3 signaling 
pathway and JAK2/STAT3 signaling 
pathway, attenuation of ERS-induced 
apoptosis 
Down-regulation of the 
phosphorylation levels of myocardial 
PERK and eIF2α, expression of 
ATF4 and CHOP in heart tissues 
(Zhao et al. 
2016) 
Bisoprolol Sprague-Dawley rats Myocardial ischemia/reperfusion 
(I/R) injury 
Inhibition of UPR signaling pathways, 
suppression of TNF-α and IL-6 
secretion, downregulation of caspase-
12 and caspase-3 expressions 
Attenuation of UPR signaling 
pathway, down-regulation of 
PERK/ATF4/ eIF2α 
(Chengcheng 
Zhang et al. 
2017) 
AG1478 and 542 (Small-
molecule EGFR inhibitors) 
C57BL/6 mice Hyperlipidemia/obesity-induced 
cardiac injuries 
Downregulation of TLR4/c-Src, 
suppression of TNFα and IL-6 
expression 
Reduction of cardiac inflammatory 
injuries 
(Li et al. 2016) 
Adiponectin U0126 
(ERK1/2 inhibitor) 
 Lipotoxicity-induced 
cardiomyopathy 
 
Inhibition of the caspase-3 and PARP 
activity, inhibition of ERK1/2 
signaling pathway, activation of the 
Akt signaling pathway 
Increase protein level of PI3K/Akt 
and decrease the protein level of 
ERK1/2 
(Wei et al. 
2012) 
Thioredoxin 2 Wistar rats Diabetic cardiomyopathy  Diminish high glucose-induced 
mitochondrial oxidative damage and 
improved ATP production 
 (Li et al. 2017) 
D942 (Small molecule) and 
curcumin (Combination 
treatment) 
C57BL/6 mice Myocardial ischemia/reperfusion 
(I/R) injury 
Activation of AMPK pathway or 
inhibition of mTOR signaling  
Upregulates autophagy and promotes 
cell survival 
(Yang et al. 
2013) 
Tauroursodeoxycholic 
Acid (Chemical chaperone) 
Transgenic calreticulin 
mice hearts (Heart CRT+) 
Heart failure  Inhibition of IRE1α pathway of the 
UPR 
Prevents cardiac fibrosis and 
preserve heart function 
(Groenendyk 
et al. 2016) 
Metformin (AMPK 
activator) 
Diabetic obese mice Cardiomyopathy  Activation of AMPK-induced PPARδ Suppresses ER stress and protects 
endothelial function 
(Jung & Choi 
2016) 
Apelin-13 ------------------ Myocardial ischemia/reperfusion 
(I/R) injury 
Modulation of PERK/CHOP, 
PI3K/Akt, AMPK and ERK pathways 
Inhibits ERS-dependent apoptosis 
activation via the 
(Lee & Ozcan 
2014) 
Atorvastatin ------------------ Heart failure GRP78, Caspase-12, CHOP Inhibits ER stress-induced apoptosis (M. Liu et al. 
2016a) 
Metoprolol and 
propranolol β adrenergic 
receptor (β-AR) blockers 
Rats Hypertrophic failing hearts Downregulation of GRP78, XBP-1, 
and calmodulin kinase II (CaMKII), 
CHOP 
Suppression of ERS and ERS-
mediated apoptosis 
(M. Liu et al. 
2016a) 
825 
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Table 4 Clinical trials of therapeutics targeting ERS and UPR 827 
Compound Disease 
Targeted 
mechanisms 
Clinical trial 
phase 
Reference 
Tauroursodeoxych
olic acid (TUDCA) 
Insulin resistance 
 
ERS N/A NCT00771901 
Sodium 
phenylbutyrate 
(PBA) 
Insulin resistance ERS N/A NCT00771901 
Liraglutide Type 2 Diabetes ERS Phase 4 NCT02344186 
Buphenyl 
Diabetes 
Insulin Resistance 
ERS Phase 4 NCT00533559 
Alpha-lipoic acid 
(ALA) 
Type 2 Diabetes 
Prediabetes 
ERS Phase-4 NCT01056497 
828 
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7 LISTS OF ABBREVIATIONS 830 
Acetylcholine enzyme (ACE) 831 
Activating transcription factor 4 (ATF4) 832 
Activating transcription factor 6 (ATF6) 833 
Adenosine triphosphate (ATP) 834 
Adiponectin (APN) 835 
Adipose tissue macrophages (ATMs) 836 
Antioxidant response element (ARE) 837 
Binding immunoglobulin protein (BiP) 838 
Cardiovascular dysfunction (CVD) 839 
Cardiovascular system (CVS) 840 
C homologous protein (CHOP) 841 
C-Jun N-terminal kinase (c-JNK) 842 
A cluster of differentiation 36 (CD36) 843 
Coronary artery disease (CAD) 844 
C-reactive protein (CRP) 845 
Cyclooxygenase-2 (COX-2) 846 
Danger-associated molecular patterns (DAMPs) 847 
Deoxyribonucleic acid (DNA) 848 
Diabetic cardiomyopathy (DCM) 849 
Diacylglycerols (DAGs) 850 
Endoplasmic reticulum (ER) 851 
Endoplasmic reticulum-associated degradation (ERAD) 852 
Endoplasmic reticulum stress (ERS) 853 
Endoplasmic reticulum stress response element (ERSE) 854 
  Running Title 
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Endothelial nitric oxide synthase (eNOS) 855 
Fatty acid translocase (FAT) 856 
Echocardiography (ECG) 857 
An extracellular signal-regulated kinase (ERK) 858 
Fibroblast growth factor (FGF) 859 
Free fatty acids (FFA) 860 
Glucose regulated protein 78 (GRP78) 861 
Glucose regulated protein 94 (GRP94) 862 
Glucose transporter 1 (GLUT1) 863 
Glucose transporter 4 (GLUT4) 864 
Glutathione peroxidase (GPx) 865 
Growth arrest and DNA-damage-inducible protein 34 (GADD34) 866 
Glycosylated hemoglobin (HbA1c) 867 
Heme oxygenase-1 (HO-1) 868 
Hydrogen peroxide (H2O2) 869 
Hydroxyl radicals (HO) 870 
Initiation factor 2a (eIF2a) 871 
Inositol-requiring enzyme 1 (IRE1) 872 
Insulin receptor substrate 1 (IRS-1) 873 
Insulin receptor substrate 2 (IRS-2) 874 
Interleukin-6 (IL-6) 875 
Intima-media thickness (IMT) 876 
Intracellular adhesion molecule 1 (ICAM-1) 877 
Left ventricular dysfunction (LVD) 878 
Lipopolysaccharide (LPS) 879 
Low-density lipoprotein (LDL) 880 
  Running Title 
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Lypoxidases (LO) 881 
Mitochondrial NADPH oxidases (NOX) 882 
Myeloperoxidases (MPO) 883 
Nitric oxide (NO) 884 
N-terminus of ATF6a (ATF6N) 885 
Nuclear E2-related factor-2 (Nrf2) 886 
Nuclear factor- kappa B (NFκB) 887 
Nucleotide oligomerization domain (NOD) 888 
Oxidized phospholipids (OxPL) 889 
Pathogen-associated molecular patterns (PAMPs) 890 
Pattern-recognition receptors (PRRs) 891 
Peroxynitrite (OONO−) 892 
PKR-like ER kinase (PERK) 893 
Protein disulfide isomerase (PDI) 894 
Reactive oxygen species (ROS) 895 
Receptor for advanced glycation end-products (RAGE) 896 
Singlet oxygen (O2) 897 
Site one proteases (S1P) 898 
Site two proteases (S2P) 899 
Spliced X-box binding protein 1 (sXBP1) 900 
Subcutaneous adipose tissue (SAT) 901 
Superoxide (−O2) 902 
Superoxide dismutase (SOD) 903 
Triacylglycerides (TAGs) 904 
Toll-like receptors (TLRs) 905 
Tumor necrosis factor- α (TNF- α) 906 
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Tumor necrosis factor-α-receptor-associated factor 2 (TRAF2) 907 
Type-2 diabetes mellites (T2DM) 908 
Vascular cell adhesion molecule 1 (VCAM-1) 909 
Ventricular hypertrophy (LVH) 910 
Very low-density lipoprotein (VLDL) 911 
Visceral adipose tissue (VAT) 912 
World Health Organization (WHO) 913 
Xanthine oxidases (XO) 914 
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